We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Peak Pharmaceuticals Inc (PK) | USOTC:PKPH | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.55 | 1.56 | 2.59 | 0.00 | 01:00:00 |
Nevada
|
|
26-1973257
|
(State
or other jurisdiction of incorporation or
organization)
|
|
(I.R.S.
Employer Identification No.)
|
Large
accelerated filer
|
☐
|
Accelerated
filer
|
☐
|
Non-accelerated
filer
|
☐
|
Smaller
reporting company
|
☑
|
(Do not
check if a smaller reporting company)
|
Emerging
growth company
|
☐
|
|
Page
|
|
|
|
|
PART I.
FINANCIAL
INFORMATION
|
|
|
|
|
|
ITEM
1
|
Financial
Statements
|
3
|
|
|
|
|
Condensed
Consolidated Balance Sheets as of December 31, 2016 (unaudited) and
September 30, 2016
|
3
|
|
|
|
|
Condensed
Consolidated Statements of Operations for the Three Months Ended
December 31, 2016 and 2015 (unaudited)
|
4
|
|
|
|
|
Condensed
Consolidated Statements of Cash Flows for the Three Months Ended
December 31, 2016 and 2015 (unaudited)
|
5
|
|
|
|
|
Notes
to Condensed Consolidated Financial Statements
(unaudited)
|
7
|
|
|
|
ITEM
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
10
|
|
|
|
ITEM
3.
|
Quantitative
and Qualitative Disclosures about Market Risk
|
14
|
|
|
|
ITEM
4.
|
Controls
and Procedures
|
14
|
|
|
|
PART II.
OTHER
INFORMATION
|
|
|
|
|
|
ITEM
1.
|
Legal
Proceedings
|
15
|
|
|
|
ITEM
1A.
|
Risk
Factors
|
15
|
|
|
|
ITEM
2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
16
|
|
|
|
ITEM
3.
|
Defaults
Upon Senior Securities
|
16
|
|
|
|
ITEM
4.
|
Mine
Safety Disclosures
|
16
|
|
|
|
ITEM
5.
|
Other
Information
|
16
|
|
|
|
ITEM
6.
|
Exhibits
|
17
|
|
|
|
SIGNATURES
|
18
|
|
For the
Three Months Ended
|
|
|
December 31,
|
|
|
2016
|
2015
|
Operating
expenses (income):
|
|
|
General
and administrative
|
$
1,883
|
$
101,659
|
Depreciation
and amortization
|
-
|
3,346
|
Equity
based compensation
|
-
|
280,053
|
Total
operating expenses
|
1,883
|
385,058
|
|
|
|
Operating
loss
|
(1,883
)
|
(385,058
)
|
|
|
|
Loss
from continuing operations
|
(1,883
)
|
(385,058
)
|
|
|
|
Income
from operations of discontinued Canna-Pet component
|
-
|
71,099
|
|
|
|
Net
loss
|
$
(1,883
)
|
$
(313,959
)
|
|
|
|
Per
share information:
|
|
|
Basic
weighted average shares outstanding
|
78,363,562
|
78,363,562
|
Diluted
weighted average shares outstanding
|
78,363,562
|
78,363,562
|
|
|
|
Continuing
operations:
|
|
|
Net
loss per share - basic and diluted
|
$
(0.00
)
|
$
(0.00
)
|
|
|
|
Discontinued
operations:
|
|
|
Net
loss per share - basic and diluted
|
$
(0.00
)
|
$
0.00
|
|
Number
of Options
|
|
Exercise Price per
Share
|
|
Average
Remaining
Term in
Years
|
|
Aggregate
Intrinsic
Value at Date
of Grant
|
|
|
|
|
|
|
|
|
Outstanding October 1, 2015
|
7,416,000
|
|
$0.0067 - $0.20
|
|
|
|
-
|
Cancelled
|
(4,500,000)
|
|
|
|
|
|
-
|
Outstanding December 31, 2016 and September 30, 2016
|
2,916,000
|
|
$0.0067 - $0.20
|
|
|
|
-
|
Exercisable
|
2,916,000
|
|
$0.0067
|
|
7.20
|
|
-
|
|
Number
of Options
|
|
Exercise Price per
Share
|
|
Average
Remaining
Term
in Years
|
|
Aggregate
Intrinsic
Value at Date
of Grant
|
|
|
|
|
|
|
|
|
Outstanding December 31, 2016, September 30, 2016 and October 1,
2015
|
375,000
|
|
$0.0067
|
|
6.79
|
|
-
|
Exercisable
|
375,000
|
|
$0.0067
|
|
6.79
|
|
-
|
|
October
15, 2015
|
September
30, 2015
|
Inventory
|
$
45,436
|
$
41,705
|
Prepaid
Expenses
|
8,821
|
-
|
Deposits
|
8,179
|
8,678
|
Total
assets
|
$
62,436
|
$
50,383
|
|
|
|
Accounts
payable
|
103,548
|
124,396
|
Royalties
payable
|
39,506
|
39,506
|
Accrued
liabilities
|
285
|
15,341
|
Total
liabilities
|
143,339
|
179,243
|
Net assets
sold
|
$
80,903
|
$
128,860
|
|
2016
|
2015
|
Revenues
|
$
-
|
$
-
|
Cost of goods
sold
|
-
|
-
|
General and
administrative expenses
|
-
|
(9,804
)
|
Gain on disposal of
discontinued operations
|
-
|
80,903
|
|
$
-
|
$
71,099
|
|
December
31,
2016
|
September
30,
2016
|
Current
assets
|
$
1,179
|
$
1,304
|
Current
liabilities
|
144,520
|
142,762
|
Working capital
deficiency
|
$
(143,341
)
|
$
(141,458
)
|
|
Three
Months Ended December 31,
|
|
|
2016
|
2015
|
Net
loss
|
$
(1,883
)
|
$
(313,959
)
|
Net cash used in
operating activities
|
(126
)
|
(139,548
)
|
Net cash used in
investing activities
|
-
|
-
|
Net cash provided
by financing activities
|
-
|
-
|
Increase (decrease)
in cash
|
$
(126
)
|
$
(139,548
)
|
By: /s/
Neil Reithinger
|
|
Neil
Reithinger
|
|
Chief
Executive Officer and Chief Financial Officer (Principal Executive
Officer, Principal Financial Officer and Principal Accounting
Officer)
|
|
Date:
September 12, 2017
|
|
1 Year Peak Pharmaceuticals (PK) Chart |
1 Month Peak Pharmaceuticals (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions